SPARC seeks US FDA nod to start phase 1 trial of SBO-154 to treat advanced solid tumours: Our Bureau, Mumbai Monday, March 31, 2025, 12:15 Hrs [IST] Sun Pharma Advanced Research C ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute SecondVersamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent ...

Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

Sun Pharma Advanced Research Company (SPARC) said that it has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for its antibody-drug conjugate ...

“SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.” said Anil ...

“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...

SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally. said Anil Raghavan ...